NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Bodal Chemicals Posts Q2 FY27 Net Profit of ₹81 Cr, Up 1,259% YoY; Files Earnings Call Transcript
Bodal Chemicals released its Q2 FY27 earnings call transcript, detailing strong financial recovery. Consolidated revenue grew 77% YoY to ₹884 crore, while EBITDA surged 197% YoY to ₹128 crore with margins reaching 14.4%. Consolidated net profit jumped 1,259% YoY to ₹81 crore, driven by robust realizations in dye intermediates and improved volume across segments. For H1 FY27, consolidated revenue reached an all-time high of ₹1,599 crore (up 67% YoY) with an EBITDA of ₹203 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the Q2 FY27 earnings conference call transcript following the results announced earlier.
ஏன் இது முக்கியம்Confirms operational turnaround after multi-year margin pressure, led by structural supply restrictions in China and plant stabilization.
📅 குறுகிய காலம்Transcript provides granular management commentary confirming strong pricing trends and volume recovery.
📈 நீண்ட காலம்Structural changes in Chinese chemical capacity and integration of downstream plants could establish higher baseline earnings if sustained.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility (specifically crude and sulphur derivatives)
Subdued margins in TCCA business requiring equipment adjustments
👀 கவனிக்க வேண்டியவை
Track whether high realizations in dye intermediates sustain through H2 FY27 and monitor profitability turnaround at the Saykha benzene derivatives unit.
Bodal Chemicals Q2 FY27 Consolidated PAT Surges to ₹81.4 Cr; Revenue Up 77% YoY to ₹884 Cr
Bodal Chemicals released its Q2 & H1 FY27 investor presentation, reporting a 77% YoY increase in consolidated Q2 revenue to ₹884.0 crore (₹8,840 mn). Consolidated Q2 EBITDA surged 197% YoY to ₹127.6 crore (₹1,276 mn), with margins expanding to 14.4% from 8.6% in Q2 FY26. Consolidated net profit rose sharply to ₹81.4 crore (₹814 mn), up from ₹6.0 crore in Q2 FY26, driven by higher volumes, improved realisations in Dye Intermediates (up 88% YoY), and raw material cost pass-through. For H1 FY27, revenue reached ₹1,599.1 crore with a PAT of ₹111.8 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுBodal Chemicals reported sharp operational and margin expansion in Q2 FY27 driven by realizations in dye intermediates and initial contributions from Benzene downstream products.
ஏன் இது முக்கியம்The performance marks a significant earnings inflection, generating ₹81.4 cr PAT in a single quarter compared to ₹47.5 cr in entire FY26, showing strong operating leverage and product integration benefits.
📅 குறுகிய காலம்Market sentiment should react favorably to the massive YoY rebound in EBITDA and net profit reported in the presentation.
📈 நீண்ட காலம்Structural tailwinds from supply shifts in China and volume ramp-up from the Benzene downstream project could enhance multi-year cash flows if realizations hold.
⚠ அபாய எச்சரிக்கைகள்
Volatility in input costs (such as Sulphur and crude oil derivatives)
Potential cyclicality in global chemical demand and pricing
👀 கவனிக்க வேண்டியவை
Track whether high EBITDA margins (~14.4%) sustain in upcoming quarters as raw material prices fluctuate, and monitor the commercial ramp-up of the Benzene downstream unit at Saykha.
Bodal Chemicals Limited announced that its Board of Directors approved standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. The meeting concluded at 1:55 PM IST following review by statutory auditors M/s. B N P S and Associates LLP. Detailed operational tables and segment metrics were not extracted in this initial cover letter. Investors should reference the attached detailed limited review reports to evaluate profitability trends against the prior quarters.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுApproval and formal submission of Q2 and H1 FY27 unaudited financial statements to stock exchanges.
ஏன் இது முக்கியம்Provides updated operational visibility into margin recovery and demand conditions in the dyes and pigments sector.
Period ended: 30th செப்டம்பர் 2026Meeting duration: 1 hour 19 minutes
📅 குறுகிய காலம்Market reaction will depend on the detailed revenue and net profit figures compared to consensus expectations.
📈 நீண்ட காலம்Limited from this procedural cover letter alone; long-term performance hinges on chemical spread margins and integrated manufacturing execution.
⚠ அபாய எச்சரிக்கைகள்
Detailed P&L figures not visible in the text extract
Crude oil volatility impacting raw material margins
👀 கவனிக்க வேண்டியவை
Review the full financial statement disclosures to assess revenue growth and operating margins relative to Q1 FY27 revenue of Rs 709.04 Cr.
56% YoY Revenue Growth in Q1FY27; PAT Surges 218% to ₹30.4 Cr
Bodal Chemicals reported a strong start to FY27 with consolidated revenue reaching ₹715.2 Cr, a 56% YoY increase. Net profit (PAT) jumped significantly by 218.7% YoY to ₹30.4 Cr, driven by improved realizations and volume growth across key segments. The newly commissioned Benzene downstream division at Saykha has begun contributing to the topline, while the Turkish subsidiary Sener Boya showed robust performance. Despite higher raw material costs linked to crude oil, the company maintained an EBITDA margin of 10.5% through effective price pass-throughs.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a period of stagnant growth to a high-growth phase in Q1FY27, supported by the operationalization of new capacities and improved market demand.
ஏன் இது முக்கியம்The successful integration of the Benzene downstream division and the recovery in Dye Intermediates are critical for improving the company's historically low ROCE (7%) and managing its ₹813 Cr debt load.
Q1FY27 Revenue: ₹715.2 கோடிQ1FY27 PAT: ₹30.4 கோடிQ1 வருவாய் vs TTM வருவாய்: ~35.5%EBITDA லாப வரம்பு: 10.5%Dye Intermediates Revenue: ₹216.6 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the sharp recovery in profitability and the start of revenue contribution from the Saykha plant.
📈 நீண்ட காலம்Structural growth depends on the successful scaling of the Benzene downstream business and maintaining cost leadership through its integrated manufacturing model.
⚠ அபாய எச்சரிக்கைகள்
High sensitivity to global crude oil prices
Significant debt-to-equity ratio of 0.68
Subdued performance in Chinese and Indonesian subsidiaries
👀 கவனிக்க வேண்டியவை
Investors should monitor the quarterly ramp-up and margin contribution of the new Benzene downstream division at Saykha, as well as the impact of crude oil price volatility on raw material costs.
178% YoY PAT Growth: Bodal Chemicals Reports Q1 FY27 Standalone Profit of ₹28.78 Cr
Bodal Chemicals delivered a strong YoY performance for Q1 FY27, with standalone revenue rising 57% to ₹698.30 Cr compared to ₹444.85 Cr in the previous year's quarter. Standalone Net Profit surged 178% YoY to ₹28.78 Cr, although it saw a slight sequential decline from ₹30.52 Cr in Q4 FY26. The results were supported by a ₹2.57 Cr SGST incentive from the Punjab Industrial Incentive Scheme. However, the company faced a ₹1.31 Cr impact due to hyperinflationary accounting for its Turkish subsidiaries.
உச்சம் நம்பிக்கை
என்ன மாறியதுBodal Chemicals has significantly improved its top-line and bottom-line performance compared to the previous year, maintaining the momentum seen in late FY26.
ஏன் இது முக்கியம்The strong YoY growth indicates a recovery in the Dyes and Pigments sector and validates the company's integrated business model, which aims for cost leadership.
Standalone Revenue (Q1 FY27): ₹698.30 கோடிStandalone PAT (Q1 FY27): ₹28.78 கோடிRevenue vs TTM Revenue: ~34.7%YoY Revenue Growth: 57%YoY PAT Growth: 178%SGST Incentive recognized: ₹2.57 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the substantial YoY growth in profitability and revenue, which exceeds the quarterly average of the previous fiscal year.
📈 நீண்ட காலம்The company's focus on backward integration and international expansion through subsidiaries provides a structural growth path, though it remains sensitive to global commodity cycles.
⚠ அபாய எச்சரிக்கைகள்
Sensitivity to crude oil price fluctuations (15-20% cost impact)
Hyperinflationary risks in Turkish operations
Reliance on government incentives for a portion of revenue
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of these higher revenue levels and the impact of crude oil price volatility on margins. The upcoming AGM on September 25, 2026, may provide further clarity on international subsidiary performance.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Bodal Chemicals Promoters Declare Zero Share Encumbrance for FY 2025-26
Suresh J. Patel, on behalf of the promoter group of Bodal Chemicals Limited, has submitted a declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The filing confirms that the promoters and persons acting in concert (PAC) have not made any encumbrance, directly or indirectly, on their shareholding during the period. This annual disclosure includes eight members of the promoter group, ensuring transparency regarding the status of their equity stakes. The absence of pledged shares is typically viewed as a sign of financial stability and confidence by the company's leadership.
முக்கிய அம்சங்கள்
Promoters confirmed zero encumbrances on shares for the financial year ended March 31, 2026.Disclosure submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.The declaration covers 8 specific promoter group members including Suresh J. Patel and Ankit S. Patel.Confirmation provided to both BSE and NSE as part of annual compliance requirements.
👀 கவனிக்க வேண்டியவை
Investors can take comfort in the fact that promoter shares are unencumbered, reducing the risk of forced selling or volatility due to margin calls. This supports a stable fundamental outlook for the stock.
Bodal Chemicals FY26 PAT Surges 158% to ₹478 Million on Strong Volume Growth
Bodal Chemicals reported a strong performance for FY26, with consolidated revenue growing 16% YoY to ₹20,539 million. The company's Net Profit (PAT) saw a massive jump of 158.5%, reaching ₹478.3 million, driven by improved volumes, better realizations, and SGST incentives from the Punjab government. While the Saykha plant's overheads and hyperinflation in Turkey impacted margins, a robust Q4 recovery in Dye Intermediates and Dyestuffs signals a positive turnaround for the core business.
முக்கிய அம்சங்கள்
Consolidated FY26 Revenue grew 16.9% YoY to ₹20,539 million.Full-year PAT increased by 158.5% to ₹478.3 million from ₹185 million in FY25.Q4FY26 EBITDA margins improved to 12.0% compared to 10.9% in Q4FY25.Basic Chemicals segment revenue surged 80% YoY to ₹1,655 million in FY26.The company successfully recognized SGST incentives for Unit 12 in Punjab, boosting profitability.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to pass on raw material costs and the margin trajectory of the new Saykha benzene plant. The significant bottom-line recovery makes this a positive development for long-term shareholders.
Bodal Chemicals Approves FY26 Audited Results and Sale of Inoperative Ahmedabad Unit
Bodal Chemicals has approved its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified auditor's opinion. The Board also authorized the sale of Unit-I in Vatva, Ahmedabad, which has been inoperative since May 24, 2024, and is considered non-significant to the company's overall revenue. The auditors highlighted an emphasis of matter regarding the recognition of SGST incentive income under the Punjab Industrial Incentive Scheme. The sale of the idle unit will be conducted at prevailing market rates to streamline operations.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.Authorized the sale of Unit-I in Vatva, Ahmedabad, which has been closed since May 2024.The unit being sold is not significant in terms of revenue or size relative to the company.Auditor's report includes an emphasis of matter regarding SGST incentive income recognition.The Board meeting concluded with an unmodified opinion on the annual accounts.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial statements for FY26 to assess operational performance and margin trends. The sale of the inoperative unit is a routine asset monetization move and is unlikely to impact the stock price significantly.
Bodal Chemicals Q3FY26 Revenue Up 13% to ₹5,047 Mn; PAT Slumps 95% on Higher Overheads
Bodal Chemicals reported a 12% YoY growth in 9MFY26 revenue to ₹14,633 million, driven by strong performance in Basic Chemicals and new Benzene downstream sales. However, Q3FY26 PAT plummeted 95.5% YoY to ₹2.4 million as the company faced increased interest and depreciation costs following the capitalization of the Saykha project. While the 9M PAT shows a 294% increase to ₹158 million due to a low base, quarterly margins were squeezed by a ₹17.97 million impact from the New Labour Code and hyperinflation losses in Turkey. Management expects the newly operational Saykha plant to contribute meaningfully to the bottom line in the coming quarters.
முக்கிய அம்சங்கள்
9MFY26 revenue grew 12% YoY to ₹14,633 million, while EBITDA rose 9% to ₹1,317 million.Q3FY26 EBITDA margin contracted to 7.4% from 10.4% YoY due to higher overheads and a ₹17.97 million labor code impact.Basic Chemicals segment revenue surged 40% YoY in 9MFY26 to ₹1,023 million, led by higher realization prices.The Saykha Benzene downstream project has commenced production, contributing to topline but currently offsetting profits via high depreciation and interest.Turkish subsidiary Sener Boya was impacted by hyperinflation, resulting in a ₹10 million loss during the quarter.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the capacity utilization and margin profile of the new Saykha plant, as its ability to absorb high fixed costs is critical for earnings recovery. While revenue growth is healthy, the stock may remain range-bound until quarterly profitability stabilizes.
Bodal Chemicals Q3 Profit Drops to ₹2.4M; Board Approves Sale of 40 Acres of Land
Bodal Chemicals reported a sharp decline in consolidated net profit to ₹2.42 million for Q3 FY26, down from ₹59.93 million in the previous quarter, despite a slight revenue growth to ₹4,895.69 million. The company has approved the sale of approximately 40 acres of land at its Unit-12 to buyers who will consume its byproducts, Chlorine and Hydrogen. This strategic move aims to monetize non-core assets and ensure uninterrupted production by securing captive-like consumption for byproducts. While 9-month profits show a significant year-on-year improvement to ₹157.68 million, the current quarterly performance remains under pressure.
முக்கிய அம்சங்கள்
Consolidated revenue for Q3 FY26 rose 10.4% YoY to ₹4,895.69 million compared to ₹4,434.66 million.Net profit plummeted to ₹2.42 million in Q3 FY26 from ₹54.15 million in the same quarter last year.Board approved selling 15.19 acres and 24.71 acres of land at Unit-12 to industrial buyers to facilitate byproduct consumption.9-month FY26 net profit stands at ₹157.68 million, a significant increase from ₹39.98 million in 9M FY25.Total comprehensive income for the quarter turned into a loss of ₹5.09 million due to foreign exchange translation differences.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the land sales as they address critical operational bottlenecks regarding byproduct disposal which impacts production stability. The sharp sequential drop in margins warrants caution despite the improved nine-month year-on-year trajectory.
Infomerics Valuation and Rating Limited has assigned new credit ratings to Bodal Chemicals Limited for total facilities worth INR 1127.53 crore. The long-term bank facilities of INR 957.53 crore have been rated 'IVR A-' with a 'Stable' outlook. Additionally, short-term bank facilities of INR 120.00 crore and proposed commercial paper of INR 50.00 crore received 'IVR A2+' ratings. This assignment establishes a credit profile for the company's significant debt and proposed short-term instruments.
முக்கிய அம்சங்கள்
Total facilities worth INR 1127.53 crore assigned new ratings by Infomerics.Long-term bank facilities of INR 957.53 crore rated IVR A- with a Stable outlook.Short-term bank facilities of INR 120.00 crore assigned IVR A2+ rating.Proposed Commercial Paper of INR 50.00 crore assigned IVR A2+ rating.
👀 கவனிக்க வேண்டியவை
The investment-grade rating reflects a moderate degree of safety regarding debt obligations. Investors should monitor if this rating leads to better refinancing terms or lower interest costs for the company.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
